Updating results

1069 results

Sort: Relevance | Date

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck

Technology appraisal guidance Published June 2008

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

Technology appraisal guidance Published June 2007

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published February 2007

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease

Technology appraisal guidance Published January 2007

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Naltrexone for the management of opioid dependence (TA115)

Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence

Technology appraisal guidance Published January 2007

Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

Technology appraisal guidance Published February 2009

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults

Technology appraisal guidance Published April 2009

Febuxostat for the management of hyperuricaemia in people with gout (TA164)

Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout

Technology appraisal guidance Published December 2008

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome

Technology appraisal guidance Published March 2008

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)

Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published February 2008

Structural neuroimaging in first-episode psychosis (TA136)

Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis

Technology appraisal guidance Published February 2008

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12

Technology appraisal guidance Published November 2007

Bortezomib monotherapy for relapsed multiple myeloma (TA129)

Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)

Technology appraisal guidance Published October 2007

Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published August 2007

Varenicline for smoking cessation (TA123)

Evidence-based recommendations on varenicline (Champix) to help people stop smoking

Technology appraisal guidance Published July 2007

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

Technology appraisal guidance Published May 2010

Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the first-line treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published September 2009

Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

Evidence-based recommendations on topotecan (Hycamtin) for treating relapsed small-cell lung cancer (SCLC)

Technology appraisal guidance Published November 2009

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Technology appraisal guidance Published March 2017

Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)

NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was

Technology appraisal guidance Published March 2017

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

Technology appraisal guidance Published October 2002

Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein

Technology appraisal guidance Published October 2002

Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

Technology appraisal guidance Published September 2002 Last updated March 2010

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018

Midostaurin for untreated acute myeloid leukaemia (TA523)

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published June 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

Evidence-based recommendations on niraparib (Zejula) for the possible treatment of ovarian, fallopian tube or peritoneal cancer in adults

Technology appraisal guidance Published July 2018

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Technology appraisal guidance Published July 2018

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy in adults

Technology appraisal guidance Published May 2018

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults

Technology appraisal guidance Published April 2018

Tocilizumab for treating giant cell arteritis (TA518)

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Technology appraisal guidance Published April 2018

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Technology appraisal guidance Published April 2018